Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03931291 · ClinicalTrials.gov registry record · Phase 2
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
A Phase 2 study of Acute Myeloid Leukemia or Myelodysplastic Syndromes, sponsored by Aprea Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 7
- Study locations
NCT03931291 is a Phase 2 study of Acute Myeloid Leukemia or Myelodysplastic Syndromes that has completed, run by Aprea Therapeutics. The registered enrollment target is 33 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT03931291, a Phase 2 study of Acute Myeloid Leukemia or Myelodysplastic Syndromes, has completed, sponsored by Aprea Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 7
- Study locations
Study Summary
A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with TP53 mutant AML or MDS.
Conditions Studied
Interventions
- DRUG APR-246
Study Locations (7)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Maryland
- Johns Hopkins, Sidney Kimmel Comprehensive Cancer Center - Baltimore
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03931291
The ClinicalTrials.gov registry entry for NCT03931291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aprea Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia or Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which APR-246 is the first listed.
NCT03931291 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT03931291 about?
NCT03931291 is a clinical study titled "APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant". A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with TP53 mutant AML or MDS.
What is the current status of trial NCT03931291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-09-16. Estimated completion is 2022-01-14.
What conditions does trial NCT03931291 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia or Myelodysplastic Syndromes.
What interventions are being tested in trial NCT03931291?
The interventions under investigation include: APR-246 (DRUG).
Who is sponsoring clinical trial NCT03931291?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03931291 being conducted?
This trial has 7 study locations across Florida, Maryland, Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.